# A Study to Test the Efficacy and Safety of Inhaled GB0139 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)

> **NCT03832946** · PHASE2 · COMPLETED · sponsor: **Galecto Biotech AB** · enrollment: 172 (actual)

## Conditions studied

- Idiopathic Pulmonary Fibrosis (IPF)

## Interventions

- **DRUG:** GB0139
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03832946
- **Lead sponsor:** Galecto Biotech AB
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-02-19
- **Primary completion:** 2023-05-17
- **Final completion:** 2023-05-17
- **Target enrollment:** 172 (ACTUAL)
- **Last updated:** 2024-05-22

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03832946

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03832946, "A Study to Test the Efficacy and Safety of Inhaled GB0139 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT03832946. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*